{"id":33983,"date":"2025-11-14T17:33:00","date_gmt":"2025-11-14T12:03:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=33983"},"modified":"2025-12-02T16:38:01","modified_gmt":"2025-12-02T11:08:01","slug":"graves-orbitopathy-treatment-landscape","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/graves-orbitopathy-treatment-landscape","title":{"rendered":"Biologics and The Battle For Sight: How A New Wave of Therapies is Transforming Graves\u2019 Orbitopathy Treatment"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0d39e3f3d04\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0d39e3f3d04\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/graves-orbitopathy-treatment-landscape\/#From_Desperation_to_Discovery\" >From Desperation to Discovery&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/graves-orbitopathy-treatment-landscape\/#The_Scale_of_the_Graves_Orbitopathy_Burden\" >The Scale of the Graves\u2019 Orbitopathy Burden<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/graves-orbitopathy-treatment-landscape\/#TEPEZZA_Teprotumumab_Breakthrough_or_Mirage\" >TEPEZZA (Teprotumumab): Breakthrough or Mirage?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/graves-orbitopathy-treatment-landscape\/#The_Chronic_Disease_Approval_A_Game-Changer\" >The Chronic Disease Approval: A Game-Changer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/graves-orbitopathy-treatment-landscape\/#Subcutaneous_TEPEZZA_Chasing_Convenience\" >Subcutaneous TEPEZZA: Chasing Convenience<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/graves-orbitopathy-treatment-landscape\/#Graves_Orbitopathy_Treatment_The_Pipeline_of_Hope\" >Graves\u2019 Orbitopathy Treatment: The Pipeline of Hope<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/graves-orbitopathy-treatment-landscape\/#Next-generation_IGF-1R_Blockade\" >Next-generation IGF-1R Blockade<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/graves-orbitopathy-treatment-landscape\/#Alternative_Biological_Pathways\" >Alternative Biological Pathways<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/graves-orbitopathy-treatment-landscape\/#Established_Biologics_Already_in_Use\" >Established Biologics Already in Use<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/graves-orbitopathy-treatment-landscape\/#Redrawing_the_Treatment_Map\" >Redrawing the Treatment Map<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.delveinsight.com\/blog\/graves-orbitopathy-treatment-landscape\/#The_Challenges_Ahead_in_Graves_Orbitopathy_Treatment\" >The Challenges Ahead in Graves\u2019 Orbitopathy Treatment<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.delveinsight.com\/blog\/graves-orbitopathy-treatment-landscape\/#Conclusion_Biology_not_Steroids_Will_Write_the_Future\" >Conclusion: Biology, not Steroids, Will Write the Future<\/a><\/li><\/ul><\/nav><\/div>\n\n<p><em>From steroid dependence to molecular precision, the Graves\u2019 orbitopathy treatment is undergoing a seismic shift. But can innovation keep pace with the burden of disease?<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-from-desperation-to-discovery-nbsp\"><span class=\"ez-toc-section\" id=\"From_Desperation_to_Discovery\"><\/span><strong>From Desperation to Discovery&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>For decades, Graves\u2019 orbitopathy stood as one of medicine\u2019s most frustrating autoimmune disorders. The condition, triggered by misguided immune attacks on the tissues around the eyes, left patients with a cruel spectrum of symptoms \u2014 bulging eyes, double vision, chronic pain, and, in some cases, permanent loss of sight.<\/p>\n\n\n\n<p>Physicians had few tools. High-dose corticosteroids were the default weapon, able to dampen inflammation but notorious for their bluntness: they often failed to halt disease progression and left behind metabolic wreckage. Radiotherapy was inconsistent. Surgery, including orbital decompression, strabismus correction, and eyelid procedures, remained a fallback, but was invasive and imperfect.<\/p>\n\n\n\n<p>For patients, the experience was often a long and grueling ordeal. Treatment alleviated symptoms but rarely addressed the underlying cause. Many lived with lasting disfigurement or visual disability.<\/p>\n\n\n\n<p>Then came 2020. With the US FDA\u2019s approval of <strong>TEPEZZA (Teprotumumab)<\/strong>, the <a href=\"https:\/\/www.delveinsight.com\/blog\/thyroid-eye-disease-treatment\">first targeted biologic for Graves\u2019 orbitopathy<\/a>, the narrative changed. Here was a drug designed not to manage the fallout but to strike at the molecular machinery of the disease itself. It was hailed as a revolution.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-scale-of-the-graves-orbitopathy-burden\"><span class=\"ez-toc-section\" id=\"The_Scale_of_the_Graves_Orbitopathy_Burden\"><\/span><strong>The Scale of the Graves\u2019 Orbitopathy Burden<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Understanding why this shift matters requires a hard look at the numbers. Graves\u2019 orbitopathy is not a rare curiosity. In the United States alone, there were approximately <strong>610,000<\/strong> diagnosed Graves\u2019 orbitopathy prevalent cases in 2024, a number projected to climb in the coming years. Women account for nearly four in five cases, reflecting the autoimmune bias toward female biology.<\/p>\n\n\n\n<p>The chronic form of the disease dominates the landscape. In 2024, more than <strong>440,000<\/strong> Americans were <a href=\"https:\/\/www.delveinsight.com\/report-store\/graves-orbitopathy-epidemiology-forecast\">living with chronic Graves\u2019 orbitopathy<\/a>, compared to about <strong>170,000<\/strong> with acute disease. That matters because chronic disease is where treatments often falter \u2014 once the inflammatory blaze cools, fibrotic scarring remains, leaving patients with enduring functional and cosmetic issues.<\/p>\n\n\n\n<p>Behind every statistic is a human toll: patients struggling with impaired vision, altered appearance, psychological distress, and disrupted careers. The economic cost, while harder to quantify, is profound \u2014 lost productivity, high healthcare utilization, and, increasingly, the price of advanced therapies.<\/p>\n\n\n\n<p><em>\u201cBehind every case number lies a face changed, a career interrupted, a life reshaped.\u201d<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-tepezza-teprotumumab-breakthrough-or-mirage\"><span class=\"ez-toc-section\" id=\"TEPEZZA_Teprotumumab_Breakthrough_or_Mirage\"><\/span><strong>TEPEZZA (Teprotumumab): Breakthrough or Mirage?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Teprotumumab arrived with extraordinary promise. A monoclonal antibody targeting the <strong>Insulin-like Growth Factor-1 Receptor (IGF-1R)<\/strong>, it was the first therapy to interrupt the pathogenic cascade driving Graves\u2019 orbitopathy directly.<\/p>\n\n\n\n<p>In clinical trials, the results stunned even seasoned ophthalmologists. Patients experienced rapid reductions in proptosis, in some cases rivalling those achieved with orbital decompression surgery. Diplopia improved, inflammation subsided, and quality-of-life scores rose dramatically.<\/p>\n\n\n\n<p>For the first time, medicine seemed to offer not just palliation but genuine disease modification.<\/p>\n\n\n\n<p>Yet, as with all breakthroughs, reality has proven more complicated<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Durability of benefit:<\/strong> Not all patients maintain long-term responses. Relapses and incomplete responses remain challenges.<\/li>\n\n\n\n<li><strong>Safety concerns: <\/strong>Adverse events such as hearing impairment and hyperglycemia are nontrivial and may limit use in certain populations.<\/li>\n\n\n\n<li><strong>Access and affordability: <\/strong>In the US, a full treatment course costs more than <strong>USD 300,000<\/strong>, sparking payer resistance and excluding many patients from access. Even in markets where regulatory approval has been obtained, such as the EU, UK, and Japan, restrictive reimbursement policies threaten to blunt the impact.<\/li>\n<\/ul>\n\n\n\n<p>Teprotumumab is undeniably a milestone, but it is not the end of the journey. If anything, it has spotlighted both the potential and the limitations of biologics in this disease.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-the-chronic-disease-approval-a-game-changer\"><span class=\"ez-toc-section\" id=\"The_Chronic_Disease_Approval_A_Game-Changer\"><\/span><strong>The Chronic Disease Approval: A Game-Changer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Originally approved only for active disease, Teprotumumab received an additional US approval in 2023 for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/graves-orbitopathy-market\">treatment of chronic Graves\u2019 orbitopathy<\/a>. This was a watershed moment. For the first time, patients with chronic, inactive disease \u2014 often marked by fibrotic changes traditionally seen as unresponsive to systemic therapy \u2014 gained access to a targeted medical option.<\/p>\n\n\n\n<p>This approval also reshaped the competitive pipeline. Agents like <strong>Veligrotug (VRDN-001)<\/strong> and other IGF-1R inhibitors were already positioning themselves in chronic disease, but Teprotumumab\u2019s label expansion raised the bar. Now, pipeline Graves\u2019 orbitopathy drugs must not only match Teprotumumab\u2019s efficacy but also demonstrate advantages in durability, safety, or convenience.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/sample-request\/graves-orbitopathy-market\"><img decoding=\"async\" width=\"1024\" height=\"397\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/29162000\/TEPEZZA-Developmental-Timeline-1024x397.jpg\" alt=\"TEPEZZA-Developmental-Timeline\" class=\"wp-image-28915\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/29162000\/TEPEZZA-Developmental-Timeline-1024x397.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/29162000\/TEPEZZA-Developmental-Timeline-300x116.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/29162000\/TEPEZZA-Developmental-Timeline-150x58.jpg 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/29162000\/TEPEZZA-Developmental-Timeline-768x298.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/29162000\/TEPEZZA-Developmental-Timeline-1536x596.jpg 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/29162000\/TEPEZZA-Developmental-Timeline-1568x609.jpg 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/29162000\/TEPEZZA-Developmental-Timeline.jpg 1734w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-subcutaneous-tepezza-chasing-convenience\"><span class=\"ez-toc-section\" id=\"Subcutaneous_TEPEZZA_Chasing_Convenience\"><\/span><strong>Subcutaneous TEPEZZA: Chasing Convenience<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Another frontier is delivery. Teprotumumab is currently available only as an intravenous infusion, which limits accessibility and adds cost. Horizon Therapeutics, the developer, is conducting a subcutaneous trial of Teprotumumab aimed at offering the same efficacy with a more patient-friendly administration route.<\/p>\n\n\n\n<p>If successful, this could address two of the drug\u2019s biggest criticisms, inconvenience and payer pushback, while further solidifying its market dominance. However, it also intensifies competition: pipeline agents like VRDN-003, which are also subcutaneous, will have to carve out their niche in a space where convenience no longer serves as a straightforward differentiator.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-graves-orbitopathy-treatment-the-pipeline-of-hope\"><span class=\"ez-toc-section\" id=\"Graves_Orbitopathy_Treatment_The_Pipeline_of_Hope\"><\/span><strong>Graves\u2019 Orbitopathy Treatment: The Pipeline of Hope<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The arrival of Teprotumumab has catalyzed a wave of innovation. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/graves-orbitopathy-pipeline-insight\" class=\"ek-link\">Graves\u2019 orbitopathy clinical trial pipeline<\/a> is no longer a trickle; it is a race.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-next-generation-igf-1r-blockade\"><span class=\"ez-toc-section\" id=\"Next-generation_IGF-1R_Blockade\"><\/span><strong>Next-generation IGF-1R Blockade<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Veligrotug (VRDN-001), an intravenous IGF-1R antagonist, is emerging as a formidable challenger. Phase III results from the THRIVE program demonstrated robust efficacy in both active and chronic disease. In chronic patients, long neglected by clinical trials, proptosis reduction was sustained through a full year. That durability matters. In 2025, the FDA granted Breakthrough Therapy designation, accelerating timelines toward a likely 2026 launch.<\/p>\n\n\n\n<p>VRDN-003, a subcutaneous formulation, promises even greater convenience. Moving biologics into the outpatient setting could expand accessibility and reduce costs.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-alternative-biological-pathways\"><span class=\"ez-toc-section\" id=\"Alternative_Biological_Pathways\"><\/span><strong>Alternative Biological Pathways<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>FcRn inhibitors, such as <strong>Efgartigimod PH20<\/strong>, aim to reduce circulating autoantibodies\u2014a strategy with precedent in other autoimmune conditions. <strong>Batoclimab, Satralizumab (ENSPRYNG), and Lonigutamab<\/strong> represent further mechanistic bets, each probing a different node in the autoimmune cascade.<\/p>\n\n\n\n<p>The common thread is ambition: to broaden efficacy, tackle chronic disease, and move toward Graves\u2019 orbitopathy therapies that are more effective, safer, and easier to deliver.<\/p>\n\n\n\n<p><em>\u201cThe question is no longer whether biologics work \u2014 it is which biologic works best, for whom, and at what stage.\u201d<\/em><\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/sample-request\/graves-orbitopathy-market\"><img decoding=\"async\" width=\"1024\" height=\"417\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/14153255\/Graves-Orbitopathy-Biologics-Pipeline-at-a-Glance-1024x417.webp\" alt=\"Graves-Orbitopathy-Biologics-Pipeline-at-a-Glance\" class=\"wp-image-33990\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/14153255\/Graves-Orbitopathy-Biologics-Pipeline-at-a-Glance-1024x417.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/14153255\/Graves-Orbitopathy-Biologics-Pipeline-at-a-Glance-300x122.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/14153255\/Graves-Orbitopathy-Biologics-Pipeline-at-a-Glance-150x61.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/14153255\/Graves-Orbitopathy-Biologics-Pipeline-at-a-Glance-768x313.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/14153255\/Graves-Orbitopathy-Biologics-Pipeline-at-a-Glance-1536x626.webp 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/14153255\/Graves-Orbitopathy-Biologics-Pipeline-at-a-Glance.webp 1920w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-established-biologics-already-in-use\"><span class=\"ez-toc-section\" id=\"Established_Biologics_Already_in_Use\"><\/span><strong>Established Biologics Already in Use<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>While much of the excitement lies in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/graves-orbitopathy-pipeline-insight\">Graves\u2019 orbitopathy drug pipeline<\/a>, some biologics are already being used in practice, albeit off-label. <strong>Rituximab<\/strong>, a B-cell-depleting therapy, and Tocilizumab, an IL-6R blocker, have been tested in patients resistant to corticosteroids. Their results have been mixed, and neither drug has achieved the transformative impact of Teprotumumab. Still, for patients with limited options, they represent meaningful alternatives \u2014 a reminder that clinicians are already turning to biologics in the fight against this disease, even beyond approved therapies.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-redrawing-the-treatment-map\"><span class=\"ez-toc-section\" id=\"Redrawing_the_Treatment_Map\"><\/span><strong>Redrawing the Treatment Map<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>What does this wave of biologics mean for day-to-day practice? It is nothing short of a paradigm shift.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Steroids on borrowed time: <\/strong>While still first-line globally due to cost and familiarity, corticosteroids are increasingly being questioned. Their side-effect profile, limited durability, and inability to alter disease course are glaring weaknesses in the biologic era.<\/li>\n\n\n\n<li><strong>Surgery redefined: <\/strong>Orbital decompression, once a near inevitability for disfiguring proptosis, may become less common as biologics deliver surgical-level reductions noninvasively. For patients, this could mean fewer scars, fewer risks, and fewer operations.<\/li>\n\n\n\n<li><strong>Chronic disease finally addressed:<\/strong> Perhaps the most exciting frontier is the chronic, fibrotic stage of Graves\u2019 orbitopathy. Historically, once fibrosis set in, medical therapy was futile. Now, with biologics like Veligrotug showing efficacy in chronic disease, that dogma may crumble.<\/li>\n<\/ul>\n\n\n\n<p>If validated, this would be a profound shift \u2014 not only relieving acute inflammation but also altering the long-term trajectory of the disease.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-the-challenges-ahead-in-graves-orbitopathy-treatment\"><span class=\"ez-toc-section\" id=\"The_Challenges_Ahead_in_Graves_Orbitopathy_Treatment\"><\/span><strong>The Challenges Ahead in Graves\u2019 Orbitopathy Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>For all the optimism, hurdles remain<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Affordability and access:<\/strong> Teprotumumab\u2019s six-figure price tag set a precedent that few healthcare systems can sustain. Without pricing innovation, even the most effective drugs will fail to reach most patients.<\/li>\n\n\n\n<li><strong>Physician adoption: <\/strong>Outside the US, biologics remain less familiar in ophthalmology and endocrinology. Confidence will grow, but it will take time.<\/li>\n\n\n\n<li><strong>Safety signals:<\/strong> Any long-term biologic therapy must balance efficacy and immunological risk. Post-marketing surveillance will be crucial.<\/li>\n<\/ul>\n\n\n\n<p>The risk is that biologics create a two-tier world: innovation for the few, traditional steroids and surgery for the many.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-conclusion-biology-not-steroids-will-write-the-future\"><span class=\"ez-toc-section\" id=\"Conclusion_Biology_not_Steroids_Will_Write_the_Future\"><\/span><strong>Conclusion: Biology, not Steroids, Will Write the Future<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Teprotumumab cracked open a door that had been shut for decades. The next wave of biologics, from Veligrotug to <a href=\"https:\/\/www.delveinsight.com\/blog\/fcrn-inhibitors-in-20-indications\">FcRn inhibitors<\/a>, is pushing it wider. For patients, the promise is immense: therapies that are more precise, more durable, and perhaps capable of rewriting the natural history of a once intractable disease.<\/p>\n\n\n\n<p>Yet optimism must be tempered with realism. Prices remain prohibitive, access is uneven, and long-term outcomes are not fully known. Graves\u2019 orbitopathy is entering its biologic era \u2014 but whether this becomes a true renaissance will depend as much on health policy and pricing reform as on science.<\/p>\n\n\n\n<p><em>\u201cThe coming decade will determine whether Graves\u2019 orbitopathy remains a story of incremental progress \u2014 or becomes a showcase of how biologics can transform an autoimmune disease once thought untouchable.\u201d<\/em><\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/graves-orbitopathy-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/17143000\/Graves-Orbitopathy-Market-Outlook-1024x194.webp\" alt=\"Graves Orbitopathy Market Outlook\" class=\"wp-image-33994\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/17143000\/Graves-Orbitopathy-Market-Outlook-1024x194.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/17143000\/Graves-Orbitopathy-Market-Outlook-300x57.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/17143000\/Graves-Orbitopathy-Market-Outlook-150x28.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/17143000\/Graves-Orbitopathy-Market-Outlook-768x145.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/17143000\/Graves-Orbitopathy-Market-Outlook-1536x291.webp 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/17143000\/Graves-Orbitopathy-Market-Outlook.webp 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>From steroid dependence to molecular precision, the Graves\u2019 orbitopathy treatment is undergoing a seismic shift. But can innovation keep pace with the burden of disease? From Desperation to Discovery&nbsp; For decades, Graves\u2019 orbitopathy stood as one of medicine\u2019s most frustrating autoimmune disorders. The condition, triggered by misguided immune attacks on the tissues around the eyes, [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":33987,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[22758,22760,22759,17971,22761],"industry":[17225],"therapeutic_areas":[17244],"class_list":["post-33983","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-graves-orbitopathy-2","tag-graves-orbitopathy-market","tag-graves-orbitopathy-treatment","tag-tepezza","tag-teprotumumab","industry-pharmaceutical","therapeutic_areas-ophthalmology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The New Biologic Era in Graves\u2019 Orbitopathy Treatment<\/title>\n<meta name=\"description\" content=\"From steroid dependence to molecular precision, the Graves\u2019 orbitopathy treatment is undergoing a seismic shift.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/graves-orbitopathy-treatment-landscape\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The New Biologic Era in Graves\u2019 Orbitopathy Treatment\" \/>\n<meta property=\"og:description\" content=\"From steroid dependence to molecular precision, the Graves\u2019 orbitopathy treatment is undergoing a seismic shift.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/graves-orbitopathy-treatment-landscape\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-14T12:03:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-02T11:08:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/14152937\/graves-orbitopathy-treatment-landscape.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"The New Biologic Era in Graves\u2019 Orbitopathy Treatment","description":"From steroid dependence to molecular precision, the Graves\u2019 orbitopathy treatment is undergoing a seismic shift.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/graves-orbitopathy-treatment-landscape","og_locale":"en_US","og_type":"article","og_title":"The New Biologic Era in Graves\u2019 Orbitopathy Treatment","og_description":"From steroid dependence to molecular precision, the Graves\u2019 orbitopathy treatment is undergoing a seismic shift.","og_url":"https:\/\/www.delveinsight.com\/blog\/graves-orbitopathy-treatment-landscape","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-11-14T12:03:00+00:00","article_modified_time":"2025-12-02T11:08:01+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/14152937\/graves-orbitopathy-treatment-landscape.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/graves-orbitopathy-treatment-landscape","url":"https:\/\/www.delveinsight.com\/blog\/graves-orbitopathy-treatment-landscape","name":"The New Biologic Era in Graves\u2019 Orbitopathy Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/graves-orbitopathy-treatment-landscape#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/graves-orbitopathy-treatment-landscape#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/14152937\/graves-orbitopathy-treatment-landscape.webp","datePublished":"2025-11-14T12:03:00+00:00","dateModified":"2025-12-02T11:08:01+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"From steroid dependence to molecular precision, the Graves\u2019 orbitopathy treatment is undergoing a seismic shift.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/graves-orbitopathy-treatment-landscape"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/graves-orbitopathy-treatment-landscape#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/14152937\/graves-orbitopathy-treatment-landscape.webp","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/14152937\/graves-orbitopathy-treatment-landscape.webp","width":466,"height":284,"caption":"graves-orbitopathy-treatment-landscape"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/11\/14152937\/graves-orbitopathy-treatment-landscape-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Graves\u2019 Orbitopathy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Graves\u2019 Orbitopathy Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Graves\u2019 Orbitopathy Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Tepezza<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Teprotumumab<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Graves\u2019 Orbitopathy<\/span>","<span class=\"advgb-post-tax-term\">Graves\u2019 Orbitopathy Market<\/span>","<span class=\"advgb-post-tax-term\">Graves\u2019 Orbitopathy Treatment<\/span>","<span class=\"advgb-post-tax-term\">Tepezza<\/span>","<span class=\"advgb-post-tax-term\">Teprotumumab<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 months ago","modified":"Updated 6 months ago"},"absolute_dates":{"created":"Posted on Nov 14, 2025","modified":"Updated on Dec 2, 2025"},"absolute_dates_time":{"created":"Posted on Nov 14, 2025 5:33 pm","modified":"Updated on Dec 2, 2025 4:38 pm"},"featured_img_caption":"graves-orbitopathy-treatment-landscape","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33983","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=33983"}],"version-history":[{"count":6,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33983\/revisions"}],"predecessor-version":[{"id":34103,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33983\/revisions\/34103"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/33987"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=33983"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=33983"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=33983"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=33983"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=33983"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}